HC Wainwright Begins Coverage on Corvus Pharmaceuticals (NASDAQ:CRVS)

HC Wainwright assumed coverage on shares of Corvus Pharmaceuticals (NASDAQ:CRVS) in a report issued on Thursday, Marketbeat reports. The firm issued a buy rating and a $11.00 price target on the stock.

A number of other analysts have also recently weighed in on the stock. Mizuho raised shares of Corvus Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a report on Tuesday, October 22nd. Oppenheimer lifted their price target on shares of Corvus Pharmaceuticals from $8.00 to $14.00 and gave the stock an “outperform” rating in a research note on Wednesday, November 13th. LADENBURG THALM/SH SH upped their price objective on shares of Corvus Pharmaceuticals from $12.00 to $21.00 and gave the company a “buy” rating in a research note on Monday, September 16th. Finally, StockNews.com cut Corvus Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Thursday, October 31st. One equities research analyst has rated the stock with a sell rating, four have assigned a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $12.38.

Corvus Pharmaceuticals Stock Performance

NASDAQ:CRVS opened at $5.43 on Thursday. Corvus Pharmaceuticals has a 1 year low of $1.30 and a 1 year high of $10.00. The stock has a market cap of $348.92 million, a P/E ratio of -5.84 and a beta of 1.05. The stock has a 50-day simple moving average of $7.72 and a 200-day simple moving average of $5.26.

Institutional Trading of Corvus Pharmaceuticals

Large investors have recently bought and sold shares of the business. Cubist Systematic Strategies LLC purchased a new position in shares of Corvus Pharmaceuticals in the 2nd quarter valued at approximately $44,000. Nwam LLC acquired a new stake in shares of Corvus Pharmaceuticals during the third quarter worth $53,000. XTX Topco Ltd purchased a new position in Corvus Pharmaceuticals in the 3rd quarter valued at $74,000. Virtu Financial LLC acquired a new position in Corvus Pharmaceuticals in the 3rd quarter valued at $83,000. Finally, Oppenheimer & Co. Inc. purchased a new position in Corvus Pharmaceuticals during the 3rd quarter worth $89,000. Institutional investors and hedge funds own 46.64% of the company’s stock.

About Corvus Pharmaceuticals

Corvus Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis.